Which drug should be avoided in the management of traumatic hyphema in a dark race individual?
**Core Concept**
In the management of traumatic hyphema, it is crucial to consider the patient's genetic predisposition to conditions that may affect bleeding and clotting. For individuals of African descent, a condition known as sickle cell trait (HbAS) is more prevalent, which can impact the management of traumatic hyphema.
**Why the Correct Answer is Right**
The correct answer is related to the risk of inducing sickling in patients with sickle cell trait. Sickle cell trait is a condition where a person inherits one normal hemoglobin gene and one sickle hemoglobin gene. In the presence of certain conditions, such as dehydration, hypoxia, or the use of certain medications, the sickle hemoglobin can polymerize and lead to sickling of red blood cells. This can cause vaso-occlusion and further compromise vision in patients with traumatic hyphema.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specifically address the risk of sickling in patients with sickle cell trait.
**Option B:** This option is incorrect because it may not be directly related to the management of traumatic hyphema in dark-skinned individuals.
**Option C:** This option is incorrect because it is not a specific medication that should be avoided in the management of traumatic hyphema in dark-skinned individuals.
**Clinical Pearl / High-Yield Fact**
It is essential to consider the patient's genetic background when managing traumatic hyphema, particularly in dark-skinned individuals who may have sickle cell trait.
**Correct Answer: B. Mannitol.**